ClinicalTrials.gg
CompletedNCT05044585HYPOUpdated Feb 28, 2023

Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers

An interventional study of Remote Automated Monitoring System in Hypoxia, sponsored by IHU Strasbourg. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by IHU Strasbourg · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

In this clinical study, the investigators will compare vital parameters measurements obtained using continuous data from reference monitors and continuous wireless MultiSense® monitoring patch in 30 healthy volunteers under induced and controlled hypoxia.

Read the detailed description

The MultiSense® strip is a unique, band aid-sized, clinical signal quality, connected strip for real-time monitoring of cardio-respiratory parameters. The MultiSense® strip measures in real-time, remotely and continuously 11 clinical key-indicators by being attached to the patient thorax: ECG trace, heart rate, oxygen saturation, respiratory rate and relative respiration depth, pulse transit time, plethysmographic trace, perfusion index, skin temperature, physical activity and body position. Designed to be worn continuously for at least seven days, the patient can keep the patch during his sleep or in the shower.

The aim of this study is to determine the quality of measurements of arterial blood saturation (SpO2) provided by the MultiSense® system in comparison to measurements made with a reference Pulse Oximetry System under induced hypoxia, in terms of accuracy.

The study population includes 30 healthy volunteers.

02

Conditions studied

  • Hypoxia

Browse trials for

Keywords

  • vital signs
  • connected device
  • real-time monitoring
  • hypoxia
  • SpO2
  • non-invasive blood pressure
  • cardio-respiratory monitoring
03

In context

Hypoxia

1,246 studies on the registry are indexed under Hypoxia; 239 are open to participants now.

This study's enrollment of 18 is below the median of 45 across 864 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

IHU Strasbourg is the lead sponsor of 44 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women between 18 to 50 years of age.
  • Subject able to receive and understand information related to the study and give written informed consent.
  • Subject is a non-smoker or an ex-smoker (stopped smoking for at least 6 months).
  • Subject demographics include a range of dark skin pigmentations, including at least 30% of the total pool, assessed by phototypes V and VI according to the Fitzpatrick scale (Questionnaire score between 28 and 40).
  • Subject is healthy (assessed by a physical examination AND normal ECG AND absence of medical treatment except for the birth control pill).
  • Subject authorizing the treatment of their personal data collected during the study (box checked in the consent form).
  • Subject affiliated to the French social security system.

Exclusion criteria

Exclusion Criteria:

  • Subject with antecedent of allergies to adhesives or silicone or a skin disease that would preclude the use of an adhesive.
  • Subject with an implantable device such as a pacemaker.
  • Pregnant or lactating women (assessed by a negative ß-HCG test).
  • Subject with a high-altitude stay during the previous 4 weeks (more than 1 week spent over 3,500 meters).
  • Subject with Raynaud's syndrome.
  • Subject in exclusion period (determined by a previous or a current study).
  • Subject under guardianship or trusteeship.
  • Subject under the protection of justice.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Remote Automated Monitoring System

    Two MultiSense® patches will be placed on each volunteer. The monitoring will last no more than 3 hours, during an induced and controlled hypoxia.

    Other: Remote Automated Monitoring System

Interventions

  • OtherRemote Automated Monitoring System

    The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.

06

What researchers measure

Primary outcomes

  1. Determination of the quality of measurements of arterial blood saturation (SpO2) provided by the MultiSense® system in comparison to measurements made with a reference Pulse Oximetry System, in terms of accuracy.

    Accuracy is defined as an average measurement variation less than 3.5% of the mean value to the reference standard. The data for analysis will be equally distributed across the SpO2 range of 70-100%.

    Time frame: from patch placement to patch removal, assessed up to 3 hours

Secondary outcomes

  1. Descriptive kinetic of circulating oxidative stress markers under hypoxia conditions

    comparison of circulating oxidative stress and plasma antioxidant activity markers in blood between hypoxia and normal oxygenation conditions by dosage of anion superoxide (µmol/min)

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  2. Descriptive kinetic of circulating oxidative stress markers under hypoxia conditions

    comparison of circulating oxidative stress and plasma antioxidant activity markers in blood between hypoxia and normal oxygenation conditions by dosage of lipids peroxidation (µg/mL)

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  3. Descriptive kinetic of circulating oxidative stress markers under hypoxia conditions

    comparison of circulating oxidative stress and plasma antioxidant activity markers in blood between hypoxia and normal oxygenation conditions by dosage of protein carbonylation (ng/mL)

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  4. Descriptive kinetic of circulating oxidative stress markers under hypoxia conditions

    comparison of circulating oxidative stress and plasma antioxidant activity markers in blood between hypoxia and normal oxygenation conditions by dosage of catalase (U/mg protein)

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  5. Descriptive kinetic of circulating oxidative stress markers under hypoxia conditions

    comparison of circulating oxidative stress and plasma antioxidant activity markers in blood between hypoxia and normal oxygenation conditions by dosage of superoxide dismutase (U/mg protein)

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  6. Descriptive kinetic of circulating oxidative stress markers under hypoxia conditions

    comparison of circulating oxidative stress and plasma antioxidant activity markers in blood between hypoxia and normal oxygenation conditions by dosage of glutathione (µmol/g protein)

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  7. Comparison of Mitochondrial respiration from PBMCs between hypoxia and normal oxygenation conditions.

    Mitochondrial respiration from PBMCs is assessed by high-resolution respirometry by analysis of the kinetic of the respirometry results and comparison between each hypoxia /post-hypoxia data point with the baseline.

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  8. To evaluate the impact of skin pigmentation on SpO2 determination by the MultiSense® solution.

    Comparison of the MultiSense® SpO2 performances with the reference between light and dark-pigmented subjects. Qualitative comparison of the raw PPG signal between light and dark-pigmented skin subjects.

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  9. To evaluate pulse transit time (PTT) as an indicator of blood pressure (BP) variation.

    Comparison of blood pressure variation measured by a standard cuff device with PTT variation measured by the MultiSense® acquisition system.

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  10. To evaluate the reliability of the respiration rate determined by the MultiSense® solution

    Determination of the quality of respiration rate provided by the MultiSense® patch in comparison to measurements made with reference medical devices in the hospital setting, in terms of accuracy. Accuracy is defined as an average measurement variation less than 5% of the respiration rate mean value to the reference standard.

    Time frame: from patch placement to patch removal, assessed up to 3 hours

  11. To compare the quality of MultiSense® data from a patch worn on the chest and from a patch worn on the upper back in different body posture and to evaluate the impact of strip exact localization on the chest.

    Qualitative comparison of the raw PPG signal between the two patches location for each subject (chest and back). Comparison of the SpO2 derived by each MultiSense® patch to the reference during the resting period in different lying positions (supine, prone, left and right side).

    Time frame: from patch placement to patch removal, assessed up to 3 hours

07

Study locations

1 site
  • Clinical Investigation Center & Physiology and Functional Explorations unit at NHC
    Strasbourg, 67000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05044585
Lead sponsor
IHU Strasbourg
Collaborators
Rhythm Diagnostic Systems
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Sep 13, 2021
Primary completion
Sep 13, 2022
Completion
Sep 13, 2022
Last update
Feb 28, 2023

Study contacts

Bernard Geny, Pr
principal investigator · Physiology and Functional Exploration, NHC Strasbourg, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion